Brigitte DRENO,<sup>1</sup> PIERRE LEVY,<sup>2</sup> GREGORY CAILLET,<sup>3</sup> JULIE BEHILLIL,<sup>4</sup> JEAN-MICHEL JOUBERT<sup>5</sup> and JEAN MICHEL AMICI<sup>6</sup>

<sup>1</sup> Nantes Université, INSERM, CNRS, Immunology and New Concepts in Immunotherapy, INCIT, UMR 1302/EMR6001. F-44000 Nantes, France, <sup>2</sup> Université Paris-Dauphine, Université PSL, LEDA[LEGOS], 75016 PARIS, France, <sup>3</sup> Affaires Médicales, Almirall SAS, PARIS, France, <sup>4</sup> Cerner Enviza France, PARIS, France, <sup>5</sup> Affaires Gouvernementales, Almirall SAS, PARIS, France, <sup>6</sup> Service de Dermatologie, CHU Bordeaux, Hôpital Saint-André, BORDEAUX, France

## INTRODUCTION

- Actinic keratosis (AK) is a chronic disease caused by sun exposure that presents as recurrent rough skin lesions.<sup>1</sup>
- AK is a risk factor for squamous cell carcinoma.<sup>2</sup>
- Epidemiological data on AK in France date from >25 years.
- Because advice on sun protection and treatment of AK has evolved since then, it is important to reevaluate the prevalence and burden of AK.<sup>3,4</sup>

### **OBJECTIVES**

- To collect up-to-date data on the epidemiology of AK in the general population in France.
- To characterise patients with AK and their disease.

### **METHODS**

- A postal questionnaire was sent to 15,246 individuals from a representative panel of the French population (METASKOPE).<sup>5</sup>
- This survey was conducted between November and December 2022 and consisted of 25 questions.
- Participants reporting current or previous AK lesions diagnosed by a physician constituted the study population.
- Information was collected on socio-demographic characteristics, diagnosis, lesions, care management and attitudes and expectations towards their disease.
- Participants not diagnosed by a physician were excluded.

# **RESULTS**

- Of the 15,246 participants to the survey, 615 participants reported AK diagnosed by physician.
- The mean age was 68.9±11.4 years and 310 (50.4%) were men (Table 1).

## Prevalence of AK

- The crude prevalence rate of AK was 4.0% (Fig. 1):
- slightly higher in men than in women (4.3% vs 3.8%;
  NS)
- increased with age from 1.7% in the 40-45 age group to 7.1% in the ≥80 age group (p<0.001) (Fig. 2).</li>
- higher in coastal regions than in inland regions (highest in the South-East: 5.7%; p<0.01) (Fig. 3).</li>

## Current AK

- Time since diagnosis was ≥3 years in 48.1% of the sample
- 69.3% had active AK at the time of the survey.
- 30.7% no longer had any lesions at the time of the survey.
- 103 (24.5%) reported a single lesion and 48 (11.4%) reported >10 lesions.
- Lesions were principally located on the face or neck in 327/420 participants (77.9%).

Table 1. Characteristics of participants




Figure 1. Prevalence of AK by age and gender




Figure 2. Prevalence of AK by age class





Figure 3. Prevalence of AK by region



**Diagnosis history** Less than 6 months 15.4% (N=615)>6 months < 1 year 8.8% 157 25.5% >1 y <3 years More than 3 years 48.1% 2.1% Unknown 69.3% **Active AK Disease status** Inactive AK 30.7% (N=615)**Number of current** Mean + SD  $1.96 \pm 1.14$ Missing data lesions (N=426) At least one current lesion 68.2% 24.5% Only 1 36.9% 2 to 3 23.8% 4 to 10 8.1% 11 to 25 3.3% More than 25 Localisation of 77.9% Face/Neck current lesions 32.1% Limbs (n=420)Trunk 22.1% 8.8% **Change since** Worsening 12.5% diagnosis (N=615) **Improvement** 34.6% No change 189 Complete diseappearance 30.7% 13.3% Unknown

Table 2. Characteristics of the AK disease

# CONCLUSIONS

- The crude prevalence of self-reported diagnosed AK in the French population aged ≥40 years is 4.0% (≈1.4 million people affected nationwide).
- The disease also affects younger patients with a significant life expectancy.
- 2/3 of participants had not managed to eradicate their lesions at the time of the survey.
- Early diagnosis of AK and treatment effectiveness and convenience should be improved to avoid progression to squamous cell carcinoma, which would be costly to treat.
- In addition, the use of a regular photoprotection, which is the most effective prevention strategy against relapse of AKs and the risk of development of squamous cell carcinoma should be discussed with the patient.

## REFERENCES

(1). De Oliveira et al., Int J Dermatol. 2019; 58: 400-407. (2). Fernandez Figueras; J Eur Acad Dermatol Venereol; 2017; 31 Suppl 2: 5-7. (3). Worley et al., Arch Dermatol Res. 2023; 315: 1099-1108. (4). Eisen et al. J Am Acad Dermatol. 2021; 85:e209-e233. (5). Charles et al.. Obesity. 2008; 16: 2182-2186.